Why can self adjusting cosentyx dosage be risky?

Dosage Variability and Patient Concerns

Self-adjusting dosages of Cosentyx, an injectable medication for psoriasis and psoriatic arthritis, can be risky for several reasons [1]. Cosentyx, also known as secukinumab, is a monoclonal antibody designed to target interleukin-17A (IL-17A), a protein involved in inflammation and autoimmune responses.

Why Adjustable Dosages May Be Problematic

Self-adjusting Cosentyx dosages may lead to inconsistent or inadequate treatment, which can increase the risk of disease flare-ups and worsening of symptoms [2]. Psoriasis patients need consistent and stable levels of Cosentyx to achieve optimal symptom control and prevent potential complications like joint damage.

Interactions with Other Medications

When switching between dosages of Cosentyx or adjusting the frequency of injections, there is a risk of interactions with other medications. Cosentyx can interact with certain antibiotics, antivirals, and other immune system modulators, increasing the likelihood of adverse reactions or reducing its effectiveness [3].

Immune System Suppression and Risks

Self-adjusting dosages of Cosentyx can suppress the immune system, increasing the risk of infections, especially pneumonia. Patients on Cosentyx should also be aware of other potential infection risks, such as cellulitis, pyelonephritis, and gastrointestinal infections [4].

Patient Education and Support

To mitigate the risks associated with self-adjusting Cosentyx dosages, patients should work closely with their healthcare providers to ensure a personalized treatment plan. Regular monitoring of disease activity, side effects, and laboratory values can help healthcare providers make informed decisions and adjust the treatment plan as needed.

Resources

For more information on Cosentyx and potential risks associated with self-adjusting dosages, consult your healthcare provider or resources like the Food and Drug Administration (FDA) or the manufacturer's website.

Sources:

[1] FDA. (2020). COSENTYX (secukinumab) Injection, for subcutaneous use. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761066s002lbl.pdf

[2] DrugPatentWatch.com. Secukinumab. Retrieved from https://www.drugpatentwatch.com/drugs/secukinumab

[3] MedlinePlus. Secukinumab systemic. Retrieved from https://medlineplus.gov/druginfo/meds/a614028.html

[4] Cosentyx. (n.d.). Full Prescribing Information. Retrieved from https://www.cosentyx.com/en-us/patient/prescribing-info